Impact of ATM Rs1801516 on Late Skin Reactions of Radiotherapy for Breast Cancer: Evidences from a Cohort Study and a Trial Sequential Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Nov 23

PMID 31756226

Citations 8

Authors

Salvatore Terrazzino

Sarah Cargnin

Letizia Deantonio

Carla Pisani

Laura Masini

Pier Luigi Canonico

Armando A Genazzani

Marco Krengli

Affiliations

Soon will be listed here.

Abstract

The relationship between the ataxia-telangiectasia mutated (ATM) rs1801516 gene polymorphism and risk of radiation-induced late skin side effects remains a highly debated issue. In the present study, we assessed the role of ATM rs1801516 as risk factor for radiation-induced fibrosis and telangiectasia, using the LENT-SOMA scoring scale in 285 breast cancer patients who received radiotherapy after breast conserving surgery. A systematic review with meta-analysis and trial sequential analysis (TSA) was then conducted to assess reliability of the accumulated evidence in breast cancer patients. In our cohort study, no association was found between ATM rs1801516 and grade ≥ 2 telangiectasia (GA+AA vs GG, HRadjusted: 0.699; 95%CI: 0.273-1.792, P = 0.459) or grade ≥ 2 fibrosis (GA+AA vs GG, HRadjusted: 1.175; 95%CI: 0.641-2.154, P = 0.604). Twelve independent cohorts of breast cancer patients were identified through the systematic review, of which 11 and 9 cohorts focused respectively on the association with radiation-induced fibrosis and radiation-induced telangiectasia. Pooled analyses of 10 (n = 2928 patients) and 12 (n = 2783) cohorts revealed, respectively, no association of ATM rs1801516 with radiation-induced telangiectasia (OR: 1.14; 95%CI: 0.88-1.48, P = 0.316) and a significant correlation with radiation-induced fibrosis (OR: 1.23; 95%CI: 1.00-1.51, P = 0.049), which however did not remain significant after TSA adjustment (TSA-adjusted 95%CI: 0.85-1.78). These results do not support an impact of ATM rs1801516 on late skin reactions of radiotherapy for breast cancer, nevertheless further large studies are still required for conclusive evidences.

Citing Articles

Safety of the Breast Cancer Adjuvant Radiotherapy in Ataxia-Telangiectasia Mutated Variant Carriers.

Bensenane R, Beddok A, Lesueur F, Fourquet A, Warcoin M, Le Mentec M Cancers (Basel). 2024; 16(7).

PMID: 38611095 PMC: 11010818. DOI: 10.3390/cancers16071417.

The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review.

Pereira S, Orlandi E, Deneuve S, Barcellini A, Chalaszczyk A, Behm-Ansmant I Cancers (Basel). 2022; 14(24).

PMID: 36551737 PMC: 9776433. DOI: 10.3390/cancers14246252.

A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma.

Wang Y, Xiao F, Zhao Y, Mao C, Yu L, Wang L Mol Cancer. 2022; 21(1):169.

PMID: 35999636 PMC: 9400233. DOI: 10.1186/s12943-022-01631-8.

Radiodermatitis and Fibrosis in the Context of Breast Radiation Therapy: A Critical Review.

Allali S, Kirova Y Cancers (Basel). 2021; 13(23).

PMID: 34885037 PMC: 8656525. DOI: 10.3390/cancers13235928.

Targeted Next-Generation Sequencing for the Identification of Genetic Predictors of Radiation-Induced Late Skin Toxicity in Breast Cancer Patients: A Preliminary Study.

Cargnin S, Barizzone N, Basagni C, Pisani C, Ferrara E, Masini L J Pers Med. 2021; 11(10).

PMID: 34683108 PMC: 8540941. DOI: 10.3390/jpm11100967.

References

Cole J, Arlett C, Green M, HARCOURT S, Priestley A, Henderson L . Comparative human cellular radiosensitivity: II. The survival following gamma-irradiation of unstimulated (G0) T-lymphocytes, T-lymphocyte lines, lymphoblastoid cell lines and fibroblasts from normal donors, from ataxia-telangiectasia patients and.... Int J Radiat Biol. 1988; 54(6):929-43. DOI: 10.1080/09553008814552331. View

Tanteles G, Murray R, Mills J, Barwell J, Chakraborti P, Chan S . Variation in telangiectasia predisposing genes is associated with overall radiation toxicity. Int J Radiat Oncol Biol Phys. 2012; 84(4):1031-6. DOI: 10.1016/j.ijrobp.2012.02.018. View

Andreassen C, Alsner J . Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. Radiother Oncol. 2009; 92(3):299-309. DOI: 10.1016/j.radonc.2009.06.015. View

Cintra H, Dourado Pinezi J, Machado G, de Carvalho G, Carvalho A, dos Santos T . Investigation of genetic polymorphisms related to the outcome of radiotherapy for prostate cancer patients. Dis Markers. 2013; 35(6):701-10. PMC: 3844174. DOI: 10.1155/2013/762685. View

Edvardsen H, Tefre T, Jansen L, Vu P, Haffty B, Fossa S . Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence. Radiat Oncol. 2007; 2:25. PMC: 1971057. DOI: 10.1186/1748-717X-2-25. View

Pereira S, Bodgi L, Duclos M, Canet A, Ferlazzo M, Devic C . Fast and Binary Assay for Predicting Radiosensitivity Based on the Theory of ATM Nucleo-Shuttling: Development, Validation, and Performance. Int J Radiat Oncol Biol Phys. 2018; 100(2):353-360. DOI: 10.1016/j.ijrobp.2017.10.029. View

Zschenker O, Raabe A, Boeckelmann I, Borstelmann S, Szymczak S, Wellek S . Association of single nucleotide polymorphisms in ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with clinical and cellular radiosensitivity. Radiother Oncol. 2010; 97(1):26-32. DOI: 10.1016/j.radonc.2010.01.016. View

Furukawa T, Guyatt G, Griffith L . Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol. 2002; 31(1):72-6. DOI: 10.1093/ije/31.1.72. View

Zhu M, Wang M, Shi T, Li Q, Xi P, Xia K . No association between TGFB1 polymorphisms and late radiotherapy toxicity: a meta-analysis. PLoS One. 2013; 8(10):e76964. PMC: 3793936. DOI: 10.1371/journal.pone.0076964. View

10.

Pavy J, Denekamp J, Letschert J, LITTBRAND B, Mornex F, Bernier J . EORTC Late Effects Working Group. Late Effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys. 1995; 31(5):1043-7. DOI: 10.1016/0360-3016(95)00059-8. View

11.

Terrazzino S, Deantonio L, Cargnin S, Donis L, Pisani C, Masini L . DNA Methyltransferase Gene Polymorphisms for Prediction of Radiation-Induced Skin Fibrosis after Treatment of Breast Cancer: A Multifactorial Genetic Approach. Cancer Res Treat. 2016; 49(2):464-472. PMC: 5398398. DOI: 10.4143/crt.2016.256. View

12.

Amirifar P, Ranjouri M, Yazdani R, Abolhassani H, Aghamohammadi A . Ataxia-telangiectasia: A review of clinical features and molecular pathology. Pediatr Allergy Immunol. 2019; 30(3):277-288. DOI: 10.1111/pai.13020. View

13.

Song Y, Duan M, Zhang Y, Shi W, Xia C, Dong L . ERCC2 polymorphisms and radiation-induced adverse effects on normal tissue: systematic review with meta-analysis and trial sequential analysis. Radiat Oncol. 2015; 10:247. PMC: 4665885. DOI: 10.1186/s13014-015-0558-6. View

14.

Bakkenist C, Kastan M . DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003; 421(6922):499-506. DOI: 10.1038/nature01368. View

15.

Deantonio L, Gambaro G, Beldi D, Masini L, Tunesi S, Magnani C . Hypofractionated radiotherapy after conservative surgery for breast cancer: analysis of acute and late toxicity. Radiat Oncol. 2010; 5:112. PMC: 3000406. DOI: 10.1186/1748-717X-5-112. View

16.

Fachal L, Gomez-Caamano A, Peleteiro P, Carballo A, Calvo-Crespo P, Sanchez-Garcia M . Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients. Radiother Oncol. 2012; 105(3):321-8. DOI: 10.1016/j.radonc.2012.09.013. View

17.

Cargnin S, Viana M, Sances G, Cantello R, Tassorelli C, Terrazzino S . Using a Genetic Risk Score Approach to Predict Headache Response to Triptans in Migraine Without Aura. J Clin Pharmacol. 2018; 59(2):288-294. DOI: 10.1002/jcph.1320. View

18.

Barnett G, Thompson D, Fachal L, Kerns S, Talbot C, Elliott R . A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiother Oncol. 2014; 111(2):178-85. DOI: 10.1016/j.radonc.2014.02.012. View

19.

Lilla C, Ambrosone C, Kropp S, Helmbold I, Schmezer P, von Fournier D . Predictive factors for late normal tissue complications following radiotherapy for breast cancer. Breast Cancer Res Treat. 2007; 106(1):143-50. DOI: 10.1007/s10549-006-9480-9. View

20.

Zhang Y, Liu Z, Wang M, Tian H, Su K, Cui J . Single Nucleotide Polymorphism rs1801516 in Ataxia Telangiectasia-Mutated Gene Predicts Late Fibrosis in Cancer Patients After Radiotherapy: A PRISMA-Compliant Systematic Review and Meta-Analysis. Medicine (Baltimore). 2016; 95(14):e3267. PMC: 4998797. DOI: 10.1097/MD.0000000000003267. View